Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Sarcoma 1Progression Free Survival(PFS) 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lung Neoplasms 1Genital Neoplasms, Female 1Genital Diseases, Female 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endocrine System Diseases 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Advanced Renal Cancer 1

Interventions

fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Cyclophosphamide 2Cisplatin 2Busulfan 2pembrolizumab 1durvalumab 1anlotinib 1Taxes 1Radiotherapy, Intensity-Modulated 1Pemetrexed 1Paclitaxel 1Nimorazole 1Immunotherapy 1CP protocol 1Bone Marrow Transplantation 1Bevacizumab 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms by Histologic Type × anlotinib × Clear all
NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Active not recruiting
56 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡